NCT05637931|Unknown
Plexin D1 as a Potential Biomarker inPM/DM
Evaluation of Circulating PlexinD1 as a Potential Biomarker of Polymyositis and Dermatomyositis.
Loading search results
Evaluation of Circulating PlexinD1 as a Potential Biomarker of Polymyositis and Dermatomyositis.
Sponsor study identifier
observational
66
0 countries
N/A
Study Start
December 25, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 25, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
evaluation of level of serum circulating plexin D1 on extacellular vesicles in adult PM/DM patients and juvenile dermatomysitis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 25, 2022
Actual (reported)December 6, 2022
Actual (reported)December 25, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 25, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Evaluation of circulating PlexinD1 as a potential biomarker of polymyositis and dermatomyositis.
evaluation of plexinD1in PM/DM patients
baseline
evaluation of the serum level of plexinD1
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
3 groups under the study adult polymyositis and dermatomyositis,juvenile dermatomyositis. and healthy control .22 subjects in each group.
Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006 Jun;8(3):167-73. doi: 10.1007/s11926-996-0021-7.
Li Y, Bax C, Patel J, Vazquez T, Ravishankar A, Bashir MM, Grinnell M, Diaz D, Werth VP. Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis. Theranostics. 2021 May 21;11(15):7144-7158. doi: 10.7150/thno.59152. eCollection 2021.
Eman Ahmed Hamed Omran, professor
Assiut University
Manal Hassanien, professor
Assiut University
Ahmed Abdel Khalek Hafez, lecturer
Assiut University
Helal F. Hetta, professor
Assiut University
First Submitted
November 25, 2022
First Posted
December 6, 2022
Study Start
December 25, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 25, 2023
Contact the study team to confirm eligibility.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008 Jun 28;371(9631):2201-12. doi: 10.1016/S0140-6736(08)60955-1.
Gherardi RK. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med. 2011 Apr;40(4 Pt 2):e209-18. doi: 10.1016/j.lpm.2010.12.013. Epub 2011 Mar 3.
Devhare PB, Ray RB. Extracellular vesicles: Novel mediator for cell to cell communications in liver pathogenesis. Mol Aspects Med. 2018 Apr;60:115-122. doi: 10.1016/j.mam.2017.11.001. Epub 2017 Nov 11.
Lane RE, Korbie D, Hill MM, Trau M. Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges. Clin Transl Med. 2018 May 31;7(1):14. doi: 10.1186/s40169-018-0192-7.
Turpin D, Truchetet ME, Faustin B, Augusto JF, Contin-Bordes C, Brisson A, Blanco P, Duffau P. Role of extracellular vesicles in autoimmune diseases. Autoimmun Rev. 2016 Feb;15(2):174-83. doi: 10.1016/j.autrev.2015.11.004. Epub 2015 Nov 7.
Uto K, Ueda K, Okano T, Akashi K, Takahashi S, Nakamachi Y, Imanishi T, Awano H, Morinobu A, Kawano S, Saegusa J. Identification of plexin D1 on circulating extracellular vesicles as a potential biomarker of polymyositis and dermatomyositis. Rheumatology (Oxford). 2022 Apr 11;61(4):1669-1679. doi: 10.1093/rheumatology/keab588.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 6, 2022
Record last verified: 2022-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: